Pay in 4 interest-free payments of $6.16 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Henninger, S
Gastric bypass and sleeve gastrectomy typically lead to 25-35% weight loss
First-in-human trial underway evaluating ATR-258's selective 2-adrenergic signaling in muscle Oral, first-in-class therapy aims to drive fat loss while preserving or increasing muscle mass Built on GRK2-biased signaling pathway to avoid traditional cardiovascular side effects Backed by 2025 Cell Press publication validating novel mechanism of action Signals growing momentum behind next-generation obesity therapies beyond GLP-1s ------------------------------------------------------------- Stay up to date with everything obesity through my newsletter To view or add a comment, sign in The ODYSSEY-#HCM findings were neutral from a clinical standpoint: Mavacamten use did not result in improved peak oxygen consumption or patient-reported health status in those with nonobstructive hypertrophic cardiomyopathy despite reverse remodeling as suggested by echocardiographic and plasma biomarker levels
None of that means compounded GLP-1 programs are disappearing tomorrow
